Empa T1D Full Data
Boehringer Ingelheim and Lilly present full results from EASE Phase III programme for empagliflozin as adjunct to insulin in type 1 diabetesAll investigated doses met the primary efficacy endpoint defined as a change from baseline in HbA1c versus placebo after 26 weeks of treatment Regulatory discussions initiated for empagliflozin, as adjunct to insulin, in type 1 diabetes Full results presented at the 54th European Association for the Study of Diabetes Annual Congress (EASD) and published online in Diabetes Care ahead of print1
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Diabetes | Diabetes Type 1 | Empagliflozin | Endocrinology | Insulin | Jardiance | Politics | Research | Study